Radiation, chemo, and immunotherapy for HR+ breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your breast cancer is hormone receptor positive (ER+) and HER2 negative, with a high growth rate (Ki-67 > 20%).
- Your tumor is at least 2 cm and may have spread to up to 3 lymph nodes, but not to other organs.
- You have not had any previous treatment for breast cancer.
- You are in good general health (fully active or able to do light activity).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests a combination of high-intensity focused ultrasound (HIFU, a non-invasive treatment that uses sound waves to heat and destroy tumor tissue) with the immunotherapy drug toripalimab and standard chemotherapy before surgery for women with a specific type of breast cancer (ER-positive, HER2-negative). The goal is to see if this approach can improve treatment outcomes for women with high-risk disease.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can help treat HR+/HER2- breast cancer. It is for women with early-stage breast cancer that has not spread to other parts of the body.
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
This trial tests whether adding the immunotherapy drug toripalimab to chemotherapy before surgery helps women with a certain type of breast cancer (HR+, HER2-). It aims to see if this combination works better than chemotherapy alone.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
Hear when a new HR-positive,HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.